CME : 0.25
MOC : 0.25
Hours : 0.25
Bringing Precision Medicine to Cholangiocarcinoma With Mitesh J. Borad, MD is organized by i3 Health.
Release Date: October 21, 2020
Expiration Date: October 20, 2021
i3 Health designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.
Statement of Need:
With an estimated incidence of 8,000 new cases per year, cholangiocarcinoma is a rare and aggressive tumor type that accounts for only 3% of all gastrointestinal cancers. Outcomes are poor, with 5-year survival rates ranging from 24% to as low as 2%. In this episode of Oncology Data Advisor, Mitesh J. Borad, MD, Associate Professor of Medicine and Director of the Liver and Biliary Cancer Research Program at the Mayo Clinic Cancer Center in Phoenix, Arizona, joins i3 Health for a discussion that covers the efficacy and adverse events of FGFR inhibitor therapy, ongoing research related to additional therapeutic targets, and the increasing role of precision medicine in the treatment of patients with cholangiocarcinoma.
Upon completion of this activity, participants should be able to:
• Account for tumor genomic factors when determining treatment for patients with cholangiocarcinoma
• Identify and manage toxicities from FGFR inhibitor therapy in patients with cholangiocarcinoma
Mitesh J. Borad, MD
Associate Professor of Medicine
Mayo Clinic College of Medicine
Medical oncologists and other health care professionals involved in the treatment of cholangiocarcinoma.
|Registration Type||Due Date||Price|
|Course Fee||20 Oct,2021||Free|
Contact Hours 1
- 60 Minutes
- 60 Minutes
CME 0.25 +2
Browse Online CME / CE Conferences by Specialty View All
- Clinical Pharmacology
- Emergency Medicine
- Endocrinology, Metabolism and Diabetes
- Healthcare Management
- Infectious Disease
- Medical Education
- Obstetrics and Gynecology
- Pain Management
- Pharmacy and Medicine
- Primary Care
- Pulmonary Medicine